A centre for innovation and technology in Darlington is to be given more than £10m by the Government to set up a new unit to help tackle cancers and develop flu vaccines.
The Centre for Process Innovation at Central park has won £10.65m in funding to boost the development of RNA technology, the vaccine innovation that protected millions around the world from COVID-19.
RNA is ribonucleic acid, present in all living cells and acting as a messenger carrying instructions from DNA.
The money will support the launch of a new innovation centre by CPI in Darlington, advancing the technology that is currently under development for the treatment of various cancers, flu vaccines and personalised medicines including gene therapy.
The Vaccine Taskforce granted the funding – administered by Innovate UK – for CPI’s RNA Centre of Excellence, which has the potential to make homegrown breakthroughs in the fight against a number of diseases, producing material for clinical trials which will be crucial to future vaccine development.
Read more: New Covid symptom as UK cases rise
The Centre is the only site in the UK currently able to develop and manufacture highly-specialised vaccines and therapies with the capability to manufacture millions of doses of a vaccine, if required for a future healthcare emergency.
It will provide state-of-the-art equipment and world-leading expertise to support industry with the testing, scale-up and clinical production of RNA technologies – showcasing the UK's capability in this area and helping to bring in further investment.
Speaking exclusively to The Northern Echo, Minister for Science and Investment Security Nusrat Ghani said there was the potential to make enormous homegrown breakthroughs in the fight against disease.
“The UK’s exceptional capabilities in the Life Sciences were showcased on the world stage when we became the first nation globally to approve a working COVID-19 vaccine during the pandemic," she said.
“We are now committed to boosting these capabilities even further, ensuring we are thoroughly prepared for future health emergencies and remaining at the forefront of the development of new therapies.
“This is why we are proud to be making this significant investment in CPI’s brilliant RNA facility in Darlington, a site with the potential to make enormous homegrown breakthroughs in the fight against disease.
“As Science Minster, I recognise the huge opportunity the UK has to use our world class science to help drive the new technologies, businesses and jobs of tomorrow, and to tackle global challenges. But to become a true Science Superpower, we must continue to develop outstanding talent across all parts of the UK, well beyond the “Golden Triangle” of London, Oxford and Cambridge.
“It is for this reason that we committed to increasing domestic public investment in R&D outside the Greater South East by 30% over the next 3 years, and 40% by 2030 – including in areas like Darlington, a town with a rich history in engineering and industrial innovation.
“The CPI’s RNA Centre for Excellence is a fantastic example of Levelling Up in action, and – with the potential to manufacture millions of doses of a vaccine in the event of a future healthcare emergency - represents the outstanding progress being made in our world-leading Life Sciences industry.”
The Centre will also form an important part of the UK’s commitment to future pandemic preparedness, as the government will retain priority access to the facility for up to 10 years. This will allow vaccine developers to utilise the site as required to provide additional manufacturing capacity in the event of a future health emergency or pandemic.
As part of the Centre, CPI has also established the RNA Training Academy, providing interactive courses in RNA technology alongside bespoke training at CPI facilities to ensure that companies can access the industry skills they require in the UK.
Tees Valley Mayor Ben Houchen said: “CPI is a fantastic example of a local organisation at the cutting-edge of biosciences and its new Centre of Excellence will be another string to the bow of the growing cluster on Darlington’s Central Park and our world-leading life sciences sector.
“This latest boost comes on the back of the amazing work of the sector in the fight against coronavirus. This funding will help our scientists make even more leaps forward and breakthroughs, having a huge impact on lives across the UK and beyond. Funding of our research centres, labs and manufacturing space will help create high-quality, highly-skilled and well-paid jobs in the innovative industries of the future for local people.
"While we're seeing difficulties across the globe which are making times tough for many, our region continues to move forward and make huge progress thanks to investments like these - meaning the long-term future of Teesside, Darlington and Hartlepool is bright."
The Vaccine Taskforce previously supported the construction and development of CPI’s centre with funding of £26.48 million, and to date, the government has invested over £405 million to secure and scale up the UK’s vaccine manufacturing capabilities, supporting the UK’s ability to respond to future pandemics.
Read next:
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here